Related Experiment Videos
Management of bleeding gastroduodenal ulcers
Stig Borbjerg Laursen1, Henrik Stig Jørgensen, Ove B Schaffalitzky de Muckadell
1Department of Gastroenterology S, Odense University Hospital, Odense C, Denmark. Sdm@OUH.regionsyddanmark.dk
Insights
Early resuscitation and prompt endoscopy within 24 hours are key for managing bleeding gastroduodenal ulcers. High-risk patients benefit from intravenous high-dose proton pump inhibitor (PPI) therapy and a 3-day hospital stay post-hemostasis.
Area of Science:
- Gastroenterology
- Clinical Medicine
- Evidence-Based Medicine
Background:
- Gastroduodenal ulcers are a significant cause of gastrointestinal bleeding.
- Effective management strategies are crucial to reduce morbidity and mortality.
Purpose of the Study:
- To provide evidence-based guidelines for the management of bleeding gastroduodenal ulcers.
- To optimize patient outcomes through timely and appropriate interventions.
Main Methods:
- Development of a guideline by Danish experts based on published studies up to March 2011.
- Grading of evidence quality and strength of recommendations.
- Approval by the Danish Society of Gastroenterology and Hepatology.
Main Results:
- Early resuscitation and endoscopy within 24 hours reduce complications and hospital stay.
- Endoscopic hemostasis is recommended for high-risk lesions using clips, thermocoagulation, or epinephrine injection (not as monotherapy).
- Intravenous high-dose proton pump inhibitor (PPI) therapy for 72 hours post-hemostasis decreases rebleeding and mortality in high-risk patients.
Conclusions:
- Prompt endoscopic intervention and appropriate medical management, including PPI therapy, are vital for bleeding gastroduodenal ulcers.
- Careful consideration of cardiovascular versus gastrointestinal risks is necessary when restarting antiplatelet therapy (e.g., acetylsalicylic acid [ASA]).
- Prophylactic proton pump inhibitor (PPI) treatment is recommended for patients on ASA or nonsteroidal anti-inflammatory drugs (NSAIDs).
Description:
A multidisciplinary group of Danish experts developed this guideline on management of bleeding gastroduodenal ulcers. Sources of data included published studies up to March 2011. Quality of evidence and strength of recommendations have been graded. The guideline was approved by the Danish Society of Gastroenterology and Hepatology September 4, 2011.
Recommendations:
Recommendations emphasize the importance of early and efficient resuscitation. Endoscopy should generally be performed within 24 hours, reducing operation rate, rebleeding rate and duration of in-patient stay. When serious ulcer bleeding is suspected and blood found in gastric aspirate, endoscopy within 12 hours will result in faster discharge and reduced need for transfusions. Endoscopic hemostasis remains indicated for high-risk lesions. Clips, thermocoagulation, and epinephrine injection are effective in achieving endoscopic hemostasis. Use of endoscopic monotherapy with epinephrine injection is not recommended. Intravenous high-dose proton pump inhibitor (PPI) therapy for 72 hours after successful endoscopic hemostasis is recommended as it decreases both rebleeding rate and mortality in patients with high-risk stigmata. Although selected patients can be discharged promptly after endoscopy, high-risk patients should be hospitalized for at least 3 days after endoscopic hemostasis. Patients with peptic ulcer bleeding who require secondary cardiovascular prophylaxis should start receiving acetylsalicylic acid (ASA) again as soon as cardiovascular risks outweigh gastrointestinal risks. Patients in need of continued treatment with ASA or a nonsteroidal anti-inflammatory drug should be put on prophylactic treatment with PPI at standard dosage. The combination of 75mg ASA and PPI should be preferred to monotherapy with clopidogrel in patients needing anti-platelet therapy on the basis of indications other than coronary stents.
Related Concept Videos
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Peptic Ulcer Disease III: Clinical Manifestations and Complications
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...